Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Cadex Genomics Developing Liquid Biopsy-Based Test for Early Response to Cancer Therapies

Cadex Genomics Developing Liquid Biopsy-Based Test for Early Response to Cancer Therapies

Feb 27, 2019
|
Leo O'Connor
Premium

NEW YORK (GenomeWeb) — Startup Cadex Genomics expects to soon launch a laboratory-developed test that uses a real-time quantitative PCR liquid biopsy assay with retrotransposon-based quantification technology to analyze the variable length of DNA fragments from cancer cells and provide clinicians with a tool to evaluate how cancer patients diagnosed with stage IV solid tumors are responding initially to treatment. 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
15
Featured Webinar

Panel Discussion: Data Interpretation in Wastewater Surveillance for SARS-CoV-2

Sponsored by
Combinati

Detection and quantification of SARS-CoV-2 levels in wastewater can be a useful predictor of potential COVID-19 outbreaks. However, the interpretation of the surveillance data can be challenging.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Featured Webinar

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

What's Popular?

In PCR

  1. DiaSorin to Acquire Luminex for $1.8B

  2. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

  3. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  4. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

  5. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.